Matthew Taylor
Stock Analyst at Jefferies
(2.74)
# 1,959
Out of 4,937 analysts
175
Total ratings
61.68%
Success rate
11.46%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Upgrades: Buy | $143 → $145 | $134.28 | +7.98% | 14 | Jul 18, 2025 | |
| INMD InMode | Maintains: Hold | $16 → $15 | $14.11 | +6.31% | 7 | Apr 14, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $72.00 | +43.06% | 2 | Jan 8, 2025 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $78.35 | -10.66% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $307.10 | -27.39% | 14 | Aug 9, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $92.88 | -18.17% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $2.68 | +4,564.18% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $144.79 | -16.43% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $2.71 | +416.61% | 1 | Jan 19, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $47 → $45 | $11.23 | +300.71% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.50 | +0.93% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $12.96 | +308.95% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $9.48 | +153.16% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $377.58 | -8.63% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $99.26 | +30.97% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $240.49 | -4.36% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $15.68 | +27.55% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $54.67 | +55.48% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $58.65 | +27.88% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $283.90 | -13.70% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $23.69 | +161.71% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $118.41 | +77.35% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $14.97 | -19.84% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $78.86 | +58.51% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $103.14 | -51.52% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $470.08 | -55.33% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $48.85 | +96.52% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $1.33 | +426.32% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $193.50 | +37.47% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $8.51 | +88.01% | 2 | Jul 19, 2017 |
Abbott Laboratories
Jul 18, 2025
Upgrades: Buy
Price Target: $143 → $145
Current: $134.28
Upside: +7.98%
InMode
Apr 14, 2025
Maintains: Hold
Price Target: $16 → $15
Current: $14.11
Upside: +6.31%
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $72.00
Upside: +43.06%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $78.35
Upside: -10.66%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $307.10
Upside: -27.39%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $92.88
Upside: -18.17%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $2.68
Upside: +4,564.18%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $144.79
Upside: -16.43%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $2.71
Upside: +416.61%
Tandem Diabetes Care
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $11.23
Upside: +300.71%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.50
Upside: +0.93%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $12.96
Upside: +308.95%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $9.48
Upside: +153.16%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $377.58
Upside: -8.63%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $99.26
Upside: +30.97%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $240.49
Upside: -4.36%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $15.68
Upside: +27.55%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $54.67
Upside: +55.48%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $58.65
Upside: +27.88%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $283.90
Upside: -13.70%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $23.69
Upside: +161.71%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $118.41
Upside: +77.35%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $14.97
Upside: -19.84%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $78.86
Upside: +58.51%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $103.14
Upside: -51.52%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $470.08
Upside: -55.33%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $48.85
Upside: +96.52%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $1.33
Upside: +426.32%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $193.50
Upside: +37.47%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $8.51
Upside: +88.01%